Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

This study has been completed.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Sarcoma
2		Additional conditions recognized in this trial
			Histiocytoma
			Histiocytoma, Benign Fibrous
			Histiocytoma, Malignant Fibrous
3		More general conditions related to this trial
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms, Connective and Soft Tissue
			Neoplasms, Connective Tissue
			Neoplasms, Fibrous Tissue
4		Interventions listed in this trial
			imatinib mesylate
5		Additional drug interventions recognized in this trial
			Imatinib
6		More general drug interventions related to this trial
			Antineoplastic Agents
			Enzyme Inhibitors
			Molecular Mechanisms of Pharmacological Action
			Pharmacologic Actions
			Protein Kinase Inhibitors
			Therapeutic Uses
7		Sponsors listed in this trial
			National Cancer Institute (NCI)